Related Experiment Video
Updated: Aug 13, 2026

07:26
Isolation of Functional Cardiac Immune Cells
Published on: December 5, 2011
Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis
1Department of Medicine, Section of Respiratory Disease, Winnipeg, Manitoba, Canada.
American Journal of Respiratory and Critical Care Medicine
|October 6, 1999
Summary
Histamine H3 receptor activation worsens cardiovascular collapse in anaphylactic shock (AS) by inhibiting norepinephrine release. Blocking these receptors may improve outcomes in AS.
Area of Science:
- Cardiovascular Physiology
- Allergy and Immunology
- Pharmacology
Background:
- Anaphylactic shock (AS) involves complex autacoid actions, with unclear roles for histamine, prostaglandins, and leukotrienes in cardiovascular collapse.
- The efficacy of receptor blockers and pathway inhibitors in mitigating AS-induced cardiovascular dysfunction requires further investigation.
Purpose of the Study:
- To investigate the role of histamine receptors (H1, H2, H3) and inflammatory pathways in preventing left ventricular (LV) contractility depression during anaphylaxis.
- To determine if blocking specific histamine receptors or inflammatory pathways can prevent cardiovascular collapse in a ragweed-induced anaphylaxis model.
Main Methods:
- Utilized a ragweed-induced anaphylaxis model in animals under pentobarbital anesthesia.
- Administered H1, H2, H3 receptor blockers, cyclooxygenase, and leukotriene pathway inhibitors prior to allergen challenge.
- Measured left ventricular (LV) volumes using sonomicrometry, alongside mean arterial pressure (Pa), cardiac output (Q), and LV end-diastolic pressure (LVEDP).
Main Results:
- All treatments resulted in a ~50% decrease in Pa, Q, and LVEDP during anaphylactic shock compared to baseline.
- Histamine H3 receptor blockade significantly increased heart rate (HR) and stroke work (SW) (p < 0.05) compared to other treatment groups.
- This suggests a protective effect of H3 blockade on cardiac function during anaphylaxis.
Conclusions:
- Histamine H3 receptor activation contributes to cardiovascular collapse in anaphylactic shock.
- H3 receptor blockade may mitigate cardiovascular dysfunction by preventing the inhibition of adrenergic neural norepinephrine release.
- Targeting histamine H3 receptors presents a potential therapeutic strategy for managing anaphylactic shock.
More Related Videos
Related Concept Videos
Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

